Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2018-03-19 Earnings Release
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Earnings Release 2018
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 19, 2018, by Ritter Pharmaceuticals, Inc. It announces the release of financial results for the fourth quarter and full year ending December 31, 2017, via a press release (Exhibit 99.1). The text explicitly states that the Form 8-K includes a press release announcing financial results, which is typical for an Earnings Release. The document length is 3924 characters, which is relatively short and consistent with an 8-K earnings announcement rather than a full financial report. The document does not contain detailed financial statements or comprehensive analysis but rather a summary announcement and a press release. Therefore, the appropriate classification is Earnings Release (ER).
2018-03-19 English
Annual Report 2017
Annual Report FY 2017
2018-03-19 English
Share Issue/Capital Change 2018
Share Issue/Capital Change Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically announces a board-approved 1-for-10 reverse stock split, which is a capital structure change. The document includes a press release attached as an exhibit describing the reverse stock split. The length is 3443 characters, which is relatively short and the document is primarily an announcement of a corporate action rather than a detailed financial report. Therefore, this filing fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding stock splits and other capital changes.
2018-03-01 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-14 English
SCHEDULE 13G
Major Shareholding Notification
2018-02-13 English
PRIMARY DOCUMENT
Director's Dealing
2018-01-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.